A wave of fresh discoveries is reshaping how scientists tackle fibrosis, the scarring process that underlies many chronic diseases. Researchers found that a traditional Chinese formula, Lichong Decoction, can calm the inflammatory environment of uterine fibroids by blocking the CXCL8 signal, offering a plant‑based option for a common women's health issue. In liver disease, a drop in the mitochondrial protein LONP1 triggers a buildup of the enzyme DHODH and the metabolite orotic acid, which then activates liver‑supporting cells and worsens fibrosis in metabolic‑associated steatohepatitis (MASH). Targeting this pathway could halt scar formation. A high‑resolution multi‑omics map of aging liver cells revealed that the protein p21 drives both liver fibrosis and the spread of colorectal cancer to the liver, suggesting new ways to protect patients after chemotherapy. Cardiovascular risk is also linked to liver health: non‑alcoholic fatty liver disease (NAFLD) and its fibrosis amplify heart problems in people with high blood pressure. Innovative therapies are emerging, too. Scientists engineered CAR‑macrophages to over‑express Lgmn, boosting their ability to clear dead cells and reduce scar tissue after a heart attack. Another team used cuttlefish‑ink nanoparticles coated with CDH2 antibodies to flip scar‑forming fibroblasts back to a normal state, improving lung and liver fibrosis. Cell‑surface engineering of a synthetic extracellular matrix reprogrammed mesenchymal stem cells to become stronger anti‑fibrotic agents. Finally, moderate alcohol intake was shown to dramatically increase fibrosis risk in patients with metabolic‑associated steatotic liver disease, while the natural compound mangiferin protected against chemotherapy‑induced liver injury by modulating key inflammation pathways. Together, these findings point to a future where fibrosis can be prevented or reversed with a mix of drugs, engineered cells, and herbal medicines.
Read more